Publication details

Význam autologní transplantace u mnohočetného myelomu

Title in English The importance of autologous transplantation in multiple myeloma
Authors

POUR Luděk HÁJEK Roman ADAM Zdeněk KREJČÍ Marta VORLÍČEK Jiří

Year of publication 2009
Type Article in Periodical
Magazine / Source Vnitřní lékařství
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords multiple myeloma; autologous transplantation
Description Several randomized clinical trials in multiple myeloma (MM) completed in the last two decades have clearly shown that high-dose chemotherapy with hematopoietic stem cell support significantly increases the number of complete remissions and median overall survival in comparison to conventional chemotherapy. The median survival of MM patients treated with conventional chemotherapy is approximately 4 years in contrast to 5 to 6 years with autologous transplantation. Although high-dose chemotherapy with autologous transplantation is not curative and most patients will eventually relapse, more than 20% of patients treated using this strategy experience survival longer than 10 years. Thus, autologous transplantation is the preferred treatment option for all eligible patients with MM.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info